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Background: Routine adjuvant administration of trastuzumab (T) has been implemented in most centers, but its
economic impact has not yet been well examined.
Methods: A Markov model was constructed based on clinical data of the Herceptin Adjuvant (HERA) and the Finland
Herceptin (FinHer) trials. Costs from the perspective of a Swiss health care provider were calculated based on
resource use.
Results: On the basis of HERA data, our model yielded an overall survival rate of 71.8% for the T group versus 62.8%
for the control group [risk ratio (RR) = 0.87) after 10 years and 62.9% versus 52.7% (RR = 0.84) after 15 years. Cost-
effectiveness resulted in 40505 Euros (EUR) per life years gained (LYG) after 10 years and 19673 EUR per LYG after
15 years. For the FinHer regimen, overall survival after 10 and 15 years resulted in 81.8% versus 66.1% (RR = 0.81)
and 73.6% versus 57.0% (RR = 0.77). Costs of 8497 EUR per patient could be saved after 10 years and 9256 EUR
after 15 years compared with the control group.
Conclusion: In a long-term perspective, adjuvant T based on the HERA regimen can be considered cost-effective.
The regimen used in the FinHer trial is even cost saving, but estimations are based on a single small trial.
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introduction
Trastuzumab (T) (Herceptin, Roche, Switzerland),
a humanized monoclonal antibody that targets the human
epidermal growth factor receptor 2 (HER2), is an important
cell proliferation regulator in HER2-overexpressing breast
cancer [1]. HER2 overexpression occurs is 25% of breast
cancers and is associated with a poorer prognosis compared
with HER2-nonexpressing tumors [2]. So far, T is routinely
used for patients with HER2-positive metastatic breast cancer,
showing good efficacy and tolerability given as monotherapy as
well as in combination with chemotherapy [3]. The major side-
effect is cardiotoxicity occurring in up to 20% of patients [4].
Recently, interim results from randomized, multicenter trials
examining T as an adjuvant treatment in early stage breast
cancer overexpressing HER2 have been published [5–7].
Thereafter, T has been implemented as a standard adjuvant
treatment in combination with chemotherapy for early-stage
breast cancer in many countries.
As for other monoclonal antibodies, wholesale drug costs per
cycle for T are high compared with other chemotherapeutic
agents [8]. Neyt et al. [9] analyzed the incremental costs for
health care providers, resulting from the introduction of T in
adjuvant therapy in Belgium. They found an incremental cost
of 45 000 Euros (EUR) per patient compared with standard
regimens as doxorubicin plus cyclophosphamide or carboplatin
plus docetaxel.
However, a cost-effectiveness analysis taking into account the
long-term clinical benefits and the side-effect profile of T based
on both the Herceptin Adjuvant (HERA) trial and the Finland
Herceptin trial (FinHer) has not been published while this topic
is being discussed at conferences [10–12].
materials and methods
We developed a Markov decision model to estimate the cost-effectiveness of
adjuvant treatment of T for women with HER2-positive early breast cancer
[13, 14]. Two strategies were examined: adjuvant treatment after surgical
therapy of early breast cancer with or without T. Clinical data and the
treatment protocol were based on the interim results of the HERA, FinHer
trial and the published literature (Table 1). We simulated a hypothetical
cohort of 10 000 women of an average age of 50 year with the same entry
criteria as in the HERA and FinHer trial for a period of 15 years (Markov
cycles). The cycle length was 1 year and the applied possible disease stages
were disease-free survival, local recurrence, regional recurrence, metastatic
disease and death. For each year, we calculated the transition probabilities of
the different disease states according to Table 1. Contralateral breast cancer
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was not considered. As in the FinHer study, events were published after
a mean follow-up of 3 years; 1 year probabilities were calculated.
Furthermore, as recurrences in the FinHer study were not separately reported
as local or regional recurrences, we assumed that half of the recurrences were
regional. Costs occurring in each cycle considering different disease states
were calculated. The clinical outcome of our simulated model (e.g. overall
survival and local recurrence) was validated with published case series.
clinical data
Disease-free survival, recurrent disease and mortality in both strategies were
based on published 1-year data of the HERA trial and 3-year data of the
FinHer-trial [5, 7]. Based on survival and recurrence patterns of a large
meta-analysis for early breast cancer patients, we assumed a constant yearly
risk for local and distant recurrences for the first 5 years after adjuvant
treatment [18]. Thereafter, this risk was gradually reduced by 10% from
6th to 15th year in order to reflect the flattening of recurrence curve in
breast cancer patients after 5 years [18]. Female mortality rates for 50- to
65-year-old Swiss women were derived from the life tables published by the
Swiss Federal Statistic Office [15]. The clinical benefit of T was assumed to
last for the first 5 years in the base case, thereafter the relative risk for
recurrent and metastatic disease in the T group assumed to be the same as
in the observational group. This duration of benefit for T was indicated by
the National Institute for Health and Clinical Excellence (NICE) [19]. As
preliminary data of the HERA trial indicates that the hazard ratio for
disease-free survival of the T group is similar to that of the observational
group after 2–3 years, we conducted a scenario analysis with a 3-year benefit
only [20]. Survival probabilities for patients with local and distant recurrent
disease were extracted from the available literature (Table 1). Congestive
heart failure (CHF) was the only side-effect of T taken into account,
occurring in 1.7% of patients receiving T during the 1st year of
treatment [5]. We assumed that in these cases medical treatment for CHF
was carried out for 1 year, as T’s cardiotoxicity is usually reversible [21].
To date, in all available studies with adjuvant T treatment, no death due to
CHF occurred; hence, mortality due to side-effects was assumed to be zero.
The percentage of estrogen-positive breast cancer patients was 50% [5, 7].
cost parameters
Direct medical costs were calculated from the perspective of a Swiss health
care provider in EUR (CHF/EUR exchange rate 2006 : 1.55) as follows:
Prices of T (5.1 EUR/mg) and other drugs were derived from official Swiss
pharmacy prices [22]. Cost of hospitalization, surgery for recurrent and
metastatic disease, radiotherapy, diagnostics and palliative chemotherapy
were estimated based on resource utilization and multiplied by the official
Swiss reimbursement catalogue [23]. Charges were used as a proxy for
costs, as true opportunity costs are not readily available. We did not
determine indirect costs, such as those due to time off from work, travel
and other out-of-pocket expenses.
trastuzumab group. Cost of ambulatory administration of adjuvant T
according to the regimen used in the HERA trial (8 mg/kg loading dose and
6 mg/kg every 3 weeks) and the FinHer trial (4 mg/kg loading dose and
2 mg/kg weekly for eight cycles) including doctor’s visit and blood
examination at every cycle and electrocardiography before the first cycle
were calculated. Cost of echocardiography (245 EUR) every 3 months and
FISH analysis (150 EUR) was considered as well. For the HERA regimen,
a 440 mg and 150 mg vial of T (590 mg/8 mg/kg = 73.7 kg) vial was
calculated for the loading dose, whereas for the 6-mg/kg dose only a 440 mg
Table 1. Survival estimates, recurrence and mortality rates used in the Markov model
Reference Outcome Annual probabilities
HERA data FinHer data
After adjuvant treatment Trastuzumab group Observational group Trastuzumab group Observational group
[5, 7] Local recurrence 0.01 0.022 0.003 0.009
Regional recurrence 0.006 0.008 0.003 0.009
Metastatic disease 0.05 0.091 0.023 0.075
Death rate for first year 0.017 0.022 0.017 0.040
[15] Yearly mortality for
2nd–15th year rate
(Swiss 50-year-old women)
0.0018 (50 years) to 0.0067 (65 years)
After treatment of local recurrence
[16] Disease free 0.9
Regional recurrence 0.06
Metastatic disease 0.01
Death 0.03
Outcome after treatment
of regional recurrence
[17] Disease free 0.9
Local recurrence 0
Metastatic disease 0.05
Death 0.05
Outcome after treatment
of metastatic disease
Trastuzumab for metastatic disease No trastuzumab for metastatic disease
[3] Metastatic disease 0.78 0.67
Death 0.22 0.33
HERA, Herceptin Adjuvant; FinHer, Finland Herceptin.
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(440 mg/6 mg/kg = 73.3 kg) vial was applied. To consider additional vial
use for women weighing >74 kg, we assumed the use of an additional
150 mg vial in 15% of patients, as previously described [24]. For the FinHer
regimen, a 440 mg vial was calculated for the loading dose and a 150 mg vial
for each following administrations. As our hospital pharmacy delivers
sterile bottled vials per order in milligrams, the cost of redundant drug due
to uniform vials (150 mg and 440 mg) of the manufacturer can be saved.
This fact was assessed in the scenario analysis. Treatment withdrawal was
reported to be 8.5% in the HERA trial, which we incorporated as
discontinuations after mean 6 months in these patients.
Cost for the treatment of symptomatic CHF was extracted from the
literature. Based on a randomized trial comparing medical treatment with
high-dose versus low-dose angiotensin-converting enzyme (ACE) inhibitor,
a cost analysis was conducted for Switzerland. The costs of treating patients
with symptomatic CHF including high-dose ACE inhibitor and hospitalization
amounted to 4320 EUR yearly and was included in our cost calculation by
adjusting to 2006 by 3% yearly price inflation [25]. Furthermore, cost of
echocardiography every 3 months for the T group was considered as well. Cost
for breast surgery, adjuvant chemotherapy and radiotherapy were not
included, as these costs accrued in both the T group and the control group.
disease-free survival and local or regional recurrence. For patients with
disease-free survival, we calculated yearly costs of a 5-year hormonal therapy
with aromatase inhibitor for hormone receptor-positive patients (2195 EUR
per year), yearly gynecological examination and mammography [26]. For
patients with local and regional disease, we estimated costs for diagnosis
including mammography and sonography, surgery including hospitalization,
radiotherapy and 5-year hormonal therapy with aromatase inhibitors.
metastatic disease. As patients with metastatic disease present with various
patterns of metastasis, therapy depends on the site of metastasis. In order to
obtain ‘real world’ data, we collected resource use of patients presenting with
metastatic disease from the year 2000 to 2004 after adjuvant treatment of
stage I–III breast cancer in our clinic (n = 21) through comprehensive
retrospective patient’s chart review. We included total resource use occurring
during the first 5 years of treatment for metastatic disease and calculated
yearly costs. Yearly costs for treatment of patients with metastatic disease
resulted in 13 025 EUR per patient excluding T use. This yearly cost was
applied to cases with metastatic disease not receiving T for metastatic disease.
We did not exclude HER2-negative cases because of a low number of
patients, but costs of treatment in the metastatic setting does not significantly
differ between HER2 positive and negative apart from T administration. In
order to adapt the costs for metastatic disease of HER2-positive breast cancer
patients to current standards, we added virtually the costs of T for metastatic
disease for the first year of treatment. As T has no proven effect on brain
metastasis and not all metastatic patients receive T due to terminal disease,
we assumed that 80% of HER2-positive metastatic patients receive first-line
T administrated for 40 weeks (6 mg/kg every 3 week after a 8 mg/kg loading
dose) in average [3, 27]. First-year treatment costs for metastatic disease,
including T treatment therefore amounted at 41 412 EUR per year and
thereafter 13 025 EUR yearly. As it is yet unclear whether patients receiving T
as adjuvant therapy will be retreated with T for metastatic disease and
whether efficacy will be similar to T-naive patients, we decided to use in the
base case a retreatment rate of 50%. The NICE indicated a retreatment rate
of both 100% and 0% as unrealistic [19]. In the scenario analysis,
a retreatment rate of 80% and 20% is also examined (Table 5).
discounting
Discounting for the time, value of money was applied to costs in order to
compare alternative future levels of costs. In this analysis, an annual
discount rate of 3.0% was applied to all costs. Discounting of effectiveness
was included in the sensitivity and the scenario analysis.
sensitivity and scenario analysis
For the HERA regimen, we conducted univariate sensitivity analyses
(610%, 620%, 630%) for the following variables: prescription price of T,
yearly cost of metastatic disease, the clinical efficacy of T and the cost of
treatment of local/regional recurrence for the base case scenario.
Effectiveness was discounted at 0% (as in base case), 3%, 5% and 7%. The
base case included assumptions that had to be made due to poor evidence
regarding future clinical data, treatment, etc. Therefore, we conducted
several scenario analyses to consider these uncertainties.
For sensitivity analysis of the FinHer regimen, we applied the 5% and
95% confidence interval of the risk for recurrence and metastases into our
model, instead of the 630% as for the HERA data. This was done in order
to better reflect the associated high uncertainties of our base case due to
limited sample size of the FinHer trial.
results
base case for the HERA regimen
In our model, recurrence rates at 10 years are 10.44% for the T
group versus 15.0% for the observational (C) group [risk ratio
Table 2. Cost parameters used for different health states
Disease free survival (gynecological
examination, mammography and
aromatase inhibitor)
1345 EUR per year
Local recurrence (imaging, surgery,
hospitalization, radiotherapy,
aromatase inhibitor)
7280 EUR for first year
Regional recurrence (imaging, surgery,
hospitalization, radiotherapy,
aromatase inhibitor)
13 640 EUR for first year
Metastatic disease (imaging,
palliative surgery, radiotherapy,
chemotherapy, hormonal
therapy, hospitalization)
41 412a EUR for first year in
the control group, 27 219b
EUR for first year in the
T group and 13 025 EUR for
further years in both groups
aT treatment rate of 80%.
bT retreatment rate of 50%.
EUR, Euros; T, trastuzumab.
Table 3. Clinical characteristics of included metastatic patients
Number of patients 21
Primary localization of metastasis 8 pulmonal metastasis
8 bone metastasis
3 liver metastasis
1 brain metastasis
1 peritoneal metastasis
Outcome 17 dead after mean survival
of 11 months
4 alive at follow-up of mean
48 months
Treatment (first and second line) 11/21 taxan-containing
chemotherapy
3/21 only symptomatic therapy
9/21 bisphosphonate treatment
Mean total hospitalization time 30 days
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(RR) = 0.70] and 11.3% versus 15.8% (RR = 0.71) at 15 years.
Overall survival rate is 71.8% for T versus 62.8% for C
(RR = 0.87) at 10 years and 62.9% versus 52.7% (RR = 0.84) at
15 years, respectively. Cost-effectiveness results are listed in
Table 4. Costs for local, regional and metastatic disease are 51%
lower in the T group compared with the C group. Costs in the
T group are mainly generated by adjuvant T drug cost
accounting for 39% of total costs. In the C group, treatment
costs of metastatic disease account for 75% of total costs.
scenarios
Cost-effectiveness of different scenarios applied to our model is
summarized in Table 5.
sensitivity analysis of the HERA regimen
In the sensitivity analysis, the cost-effectiveness of T is mainly
influenced by its clinical efficacy, discounting of effectiveness
and its prescription price (Figure 2). The model shows
robustness for treatment cost of metastatic and local/regional
disease.
base case and sensitivity analysis for the
FinHer regimen
For the FinHer regimen, recurrence rates at 10 years are 4.91 %
for the T group versus 8.77% for the C group (RR = 0.55) and
5.48% versus 9.19% (RR = 0.60) at 15 years. Overall survival
after 10 and 15 years were 81.8% versus 66.1% (0.81) and
73.6% versus 57.0% (0.77), respectively (Figure 1). Costs for T
administration were 9248 EUR for this regimen compared with
39 245 EUR for the HERA regimen. Cost effectiveness results
are listed in Table 6. Costs per patient for the T group were
lower than those for the control group in the base case and
sensitivity analysis, using the 5% and 95% confidence interval
of the risk for local and distant recurrence [7].
model validation
HERA regimen. The local recurrences and overall survival rates
obtained from our model for the control group are comparable
to published large case series. Our 10-year local recurrence rate
of 15.0% is somewhat higher than the 13% reported in a meta-
analysis of HER2 positive and negative, node-positive early
breast cancers [18]. However, the HERA patient population
includes only HER2-positive patients, which is associated withTable 4. Cost-effectiveness of adjuvant trastuzumab per patient based
on the HERA trial regimen
Total cost of
trastuzumab
group (EUR)
Total cost of
comparator
group (EUR)
Incremental
cost (EUR)
LYG Cost/
LYG
(EUR)
Base case
At 5 years 53 403 27 304 26 099 0.12 212 360
At 10 years 62 656 41 559 21 097 0.52 40 505
At 15 years 67 682 47 791 19 891 1.01 19 673
HERA, Herceptin Adjuvant; EUR, Euros; LYG, life years gained.
Table 5. Cost-effectiveness using different scenarios in cost per life year
gained for the HERA regimen
Scenarios examined At 5 years
(EUR)
At 10 years
(EUR)
At 15 years
(EUR)
Clinical benefit of T
limited to 3 years
245 004 70 920 37 630
T retreatment (20%)
for metastatic
disease for patients
with adjuvant T
233 746 39 124 17 521
T retreatment (80%)
for metastatic
disease for patients
with adjuvant T
197 500 41 882 21 763
T administration in
centers with sterile
preparation of
ordered drug
dosage (saving
redundant drug)
181 219 33 157 15 888
Discounting life years
gained at 3%
245 396 51 443 27 094
HERA, Herceptin Adjuvant; EUR, Euros; T, trastuzumab.
Figure 1. Overall survival projections based on the Herceptin Adjuvant
(HERA) and the Finland Herceptin (FinHer) trials (fine lines indicate
survival probabilities used in the sensitivity analysis). (A) HERA trial and
(B) FinHer trial.
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higher recurrence rate, and therefore a recurrence rate of 15.0%
should be regarded realistic for the HERA study control group.
Overall survival in the control group of 62.8% after 10 years is
similar to published data on HER2-positive early breast cancers
ranging from 50% to 65% [28, 29].
FinHer regimen. Local recurrence rate of 8.8% in the control
group is lower than the 13% reported in the literature [18].
Overall survival of 66% after 10 years in the control group is
slightly higher than that of published data on HER2-positive
early breast cancers ranging from 50% to 65% [28, 29].
discussion
Our findings in the base case analysis and the scenario analysis
based on the HERA regimen indicate that the cost-effectiveness
ratio after 5 years is above the generally accepted 50 000 EUR
per life years gained (LYG) for new therapies [30, 31]. The main
cost driver of adjuvant T treatment is the high prescription
price of this drug. However, this costly adjuvant treatment
reduces risk of recurrences and metastasis, resulting in lower
costs for secondary and palliative treatments. Therefore, the
cost-effectiveness ratio improves in our calculation after 10 and
15 years to a threshold <50 000 EUR in both the base case and
the sensitivity analysis. Our results indicate that adjuvant
treatment may be more cost-effective on a 15-year horizon than
in the metastatic setting only [24]. Endocrine treatment of
estrogen receptor-positive early breast cancer for 5 years with
anastrozole compared with the less costly tamoxifen resulted in
96 000 US$ per LYG after 12 years and 40 600 US$ after 20
years [32]. Compared with our results, this ratio is higher and
still regarded as cost-effective for US health care system.
An important issue strongly influencing the cost-effectiveness
is the dosage and number of cycles of T. Although patient
number and unequally distributed nodal positive diseases were
major limitations of the FinHer trial, the published data of this
study considering 9 weeks of T administration are impressive
[7]. Although not yet recommended as standard therapy, we
attempted to estimate the cost-effectiveness of the FinHER
regimen with the limited clinical data available. As recurrences
are not reported in detail (local versus regional) and sample
size is very limited, a cost-effectiveness analysis is associated
with many uncertainties. Our model for the FinHer trial yielded
a low 10- and 15-year recurrence rate compared with published
literature. However, this rate is based on the six events of 116
(5.2%) patients after a mean follow-up of 3 years (H. Joensuu,
personal communication; Helsinki). In the sensitivity analysis,
we attempted to offset these high uncertainties by using the
wide ranges of the reported confidence intervals.
Interestingly, our results indicate that this 9-week regimen
might even save costs compared with no adjuvant T treatment.
In contrast, the HERA regimen is more costly than no adjuvant
T while being cost-effective. Thus, clinical and economic
efficacy of the FinHer regimen should be confirmed by larger
trials.
So far, Neyt et al. [9] conducted a cost analysis before the
publication of the clinical data of the HERA trial for the Belgian
health care system. They estimated combination chemotherapy
with T to result in total cost of 45 000 EUR for 50 year old
patients with stage III breast cancer. Depending on clinical
efficacy, the authors concluded that T may be cost-effective. In
our analysis, we used 39 000 EUR cost for T treatment
additionally to standard chemotherapy, which is comparable to
the calculation of Neyt et al. Hillner [10] estimated for the
health care system of the United States, a cost-effectiveness
ratio of 76 300 US$ per LYG after 10 years and 39 000 US$ per
LYG after 20 years. The 10-year overall survival projections
were similar to our model with 68% versus 57.2% in the T
group versus C group. He also concluded that adjuvant T may
be cost-effective in a long-term view. Furthermore, Norum and
Olsen [11] found for the health care system of Norway a cost-
effectiveness of 11 800–35 214 EUR per LYG; however, indirect
cost was also considered in this cost analysis. A cost-
effectiveness analysis for UK submitted by the manufacturer to
the NICE and presented at a conference found 2396 £ (3600
EUR) per quality-adjusted LYG [12, 19]. However, these
estimations assumed a lifetime benefit of T and a T retreatment
rate for metastatic disease of 0%. The NICE committee
Figure 2. Univariate sensitivity analysis of the base case analysis of the
Herceptin Adjuvant regimen.
Table 6. Cost-effectiveness of adjuvant trastuzumab per patient based
on the FinHer trial regimen
Total cost of
trastuzumab
group (EUR)
Total cost of
comparator
group (EUR)
Cost
savings
(EUR)
LYG
Base case
At 5 years 20 070 23 816 23746 0.27
At 10 years 28 210 36 707 28497 0.97
At 15 years 33 419 42 675 29256 1.79
5% CI of base case
At 5 years 17 955 23 816 25861 0.38
At 10 years 25 866 36 707 210 841 1.36
At 15 years 31 348 42 675 211 326 2.48
95% CI of base case
At 5 years 23 653 23 816 2163 0.04
At 10 years 32 051 36 707 24656 0.25
At 15 years 36 760 42 675 25915 0.55
FinHer, Finland Herceptin; EUR, Euros; LYG, life years gained; CI,
confidence interval.
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regarded these assumptions as too optimistic and
recommended a 5-year benefit and indicated a retreatment rate
of 100% more probable. Under these assumptions, T cost-
effectiveness resulted in 18 942 £ (28 000 EUR) per quality
adjusted LYG.
Our model yielded 17 000–38 000 EUR per LYG after 15
years for the HERA regimen under various assumptions, which
is similar to the results reported by authors mentioned above,
although that all these analyses were based on different health
care systems. In contrast to these analyses, we did not use
20 year or even longer projections, as we assume a maximum
benefit of T for the first 5 years instead of a lifelong benefit.
LYG in the T group beyond our 15-year horizon is excluded in
our analysis and the cost-effectiveness might be
underestimated. However, we chose a conservative approach as
the underlying patient population in a highly selected subgroup
of breast cancer patients. Long-term data of HER2-positive
versus -negative breast cancer patients are limited to 10 years,
thus not allowing to validate survival projections longer than
this time period. Furthermore, cost-effectiveness analysis of T
for adjuvant treatment are modeling long-term impact of T
treatment based on clinical data after 1–2 year follow-up.
Uncertainties regarding these projections are increasing the
longer the time horizon is chosen and accordingly the cost-
effectiveness results.
In our base case scenario for the HERA regimen, we used
a retreatment rate of 50% for patients receiving T for adjuvant
therapy compared with the control group receiving in 80% of
cases T for metastatic disease. However, poor evidence exists
about retreatment rate and T resistance. As the NICE was
cautious about 0% and 100% retreatment rate, the 50% is
appropriate for the base case according to our opinion [19]. In
the scenario analysis, cost-effectiveness results of 20% and 80%
retreatment rates are also shown and may be more realistic than
the 0% versus 100% submitted to the NICE by the
manufacturer. However, retreatment rate of 80% may represent
the most probable scenario in the near future, assuming that
novel costly targeted therapies will be soon available for HER2-
positive metastatic breast cancer resistant to T [33].
A crucial issue when considering cost-effectiveness of T is the
projected duration of benefit. In our base case, we assumed a
5-year benefit as recommended by the NICE. However, recent
data indicate the benefit to last not more than 2–3 years in the
HERA trial [20]. In contrast, in the Joint analysis of the
NSABP-B-31 and NCCTG-N9831 the benefit is still significant
at 3 years and may last even longer [6]. Norum et al. used in
their model, a benefit of T lasting 10 years and the
manufacturer assumed a lifelong benefit in their base case. As
shown in our scenario analysis with T’s benefit lasting 3 years
only, the cost-effectiveness is much less favorable, but still
meets the acceptability threshold of 50 000 EUR per LYG.
Interestingly, the scenario analysis shows that a significant
amount of money can be saved if T can be ordered by dosage
(in milligram) through a pharmacy as in our institution. In
contrast, the use of the two uniform vials (150 mg and 440 mg)
provided by the manufacturer is often associated with loss of
costly redundant drug.
However, our analysis has some limitations. It is based on
clinical data of 1-year and3-year analyses of two single randomized
clinical trials. The long-term clinical benefit had to be estimated
by modeling techniques. Nevertheless, adjuvant T has been
approved in many countries based on this short-term clinical data
and without any conducted cost-effectiveness studies.
Furthermore, costs were derived partially from standard
treatment guidelines in the case of local and regional recurrence
and partially from a retrospective chart review for metastatic
disease. Our sample size of patients presenting with metastatic
disease after adjuvant treatment of breast cancer is limited.
However, we think that this sample might be a representative
collection as these patients present with various patterns of
metastasis (Table 3). Unfortunately, we had to rely solely on
this data, as in Switzerland no disease-specific cost data exists.
We conclude that adjuvant T treatment may be cost-effective
in a long-term perspective based on current clinical data from
the HERA trial. The FinHer regimen clearly seems to save
money compared with no adjuvant T treatment, although its
clinical and economic efficacy should be supported by larger
clinical trials.
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